Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer

被引：1
|
作者：
Zhou, Yunxiang [1 ,2 ]
Wang, Xiaojia [3 ]
Chen, Yiding [1 ,2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Breast Surg & Oncol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Canc Inst,Key Lab Canc Prevent & Intervent,China N, Hangzhou, Zhejiang, Peoples R China
[3] Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Dept Breast Med Oncol,Canc Hosp,Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
MEDCOMM | 2023年 / 4卷 / 04期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1002/mco2.322
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Cardiotoxicity in HER2-positive breast cancer patients
    Diana Gonciar
    Lucian Mocan
    Alexandru Zlibut
    Teodora Mocan
    Lucia Agoston-Coldea
    Heart Failure Reviews, 2021, 26 : 919 - 935
  • [32] Neratinib in HER2-Positive Breast Cancer Patients
    Paranjpe, Rutugandha
    Basatneh, Dima
    Tao, Gabriel
    De Angelis, Carmine
    Noormohammed, Sobia
    Ekinci, Ekim
    Abughosh, Susan
    Ghose, Romi
    Trivedi, Meghana V.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (06) : 612 - 620
  • [33] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [34] Appearance and therapy of brain metastases in patients with HER2-positive breast cancer
    Witzel, I
    Hemminger, G.
    Ihnen, M.
    Jaenicke, F.
    Mueller, V
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S137 - S137
  • [35] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [36] Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
    Rupert Bartsch
    Catharina De Vries
    Ursula Pluschnig
    Peter Dubsky
    Zsuzsanna Bago-Horvath
    Simon P Gampenrieder
    Margaretha Rudas
    Robert M Mader
    Andrea Rottenfusser
    Christoph Wiltschke
    Michael Gnant
    Christoph C Zielinski
    Guenther G Steger
    BMC Cancer, 9
  • [37] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [38] ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER
    Farhat, Fadi
    Kattan, Joseph
    Ghosn, Marwan
    BREAST, 2015, 24 : S42 - S43
  • [39] Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
    Bartsch, Rupert
    De Vries, Catharina
    Pluschnig, Ursula
    Dubsky, Peter
    Bago-Horvath, Zsuzsanna
    Gampenrieder, Simon P.
    Rudas, Margaretha
    Mader, Robert M.
    Rottenfusser, Andrea
    Wiltschke, Christoph
    Gnant, Michael
    Zielinski, Christoph C.
    Steger, Guenther G.
    BMC CANCER, 2009, 9 : 367
  • [40] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
12345